Translational Medicine
Clinical Pharmacology & Therapeutics (2008) doi:10.1038/sj.clpt.6100378
KATP Channel Pharmacogenomics: From Bench to Bedside
S Sattiraju1, S Reyes1, GC Kane1 and A Terzic1
1Marriott Heart Disease Research Program, Division of Cardiovascular Diseases, Departments of Medicine, Molecular Pharmacology and Experimental Therapeutics, and Medical Genetics, Mayo Clinic, Rochester, Minnesota, USA
Correspondence: A Terzic, terzic.andre@mayo.edu
Received 00; Accepted 00; Published online 24 October 2007.
Abstract
Inheritance plays a significant role in defining drug response and toxicity. Advances in molecular pharmacology and modern genomics emphasize genetic variation in dictating inter-individual pharmacokinetics and pharmacodynamics. A case in point is the homeostatic ATP-sensitive potassium (KATP) channel, an established drug target that adjusts membrane excitability to match cellular energetic demand. There is an increased recognition that genetic variability of the KATP channel impacts therapeutic decision-making in human disease.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
PKA-mediated phosphorylation of the human K ATP channel: separate roles of Kir6.2 and SUR1 subunit phosphorylationThe EMBO Journal Article (01 Sep 1999)
Kir6.2 mutations causing neonatal diabetes provide new insights into Kir6.2?SUR1 interactionsThe EMBO Journal Article (06 Jul 2005)
Characterization of the rat mesangial cell type 2 sulfonylurea receptorKidney International Original Article
Maladaptive cardiac remodeling and mortality under mineralocorticoid induced hypertension following KATP channel knockoutClinical Pharmacology & Therapeutics null
See all 40 matches for Research
